[{"NetIncomeLoss_1_Q2_USD":-36421000.0,"Liabilities_0_Q2_USD":105993000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2_Q2_USD":1627000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"GeneralAndAdministrativeExpense_2_Q2_USD":32213000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":16940000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":18047000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-4379000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-279000.0,"StockIssuedDuringPeriodValueNewIssues_18_Q2_USD":356700000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":771450.0,"InterestIncomeExpenseNonoperatingNet_2_Q2_USD":-7344000.0,"InterestIncomeExpenseNonoperatingNet_1_Q2_USD":-3389000.0,"AssetsCurrent_0_Q2_USD":195252000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":3504000.0,"CommonStockSharesIssued_0_Q2_shares":19240295.0,"Assets_0_Q2_USD":219497000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":4233000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-2721000.0,"ShareBasedCompensation_2_Q2_USD":6566000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":186286000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.01,"OtherAssetsNoncurrent_0_Q2_USD":6117000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-39142000.0,"IncreaseDecreaseInOtherNoncurrentAssets_2_Q2_USD":-159000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":40837000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":20894000.0,"IncreaseDecreaseInPrepaidExpense_2_Q2_USD":-1596000.0,"EarningsPerShareBasic_1_Q2_USD":-1.9,"EarningsPerShareBasic_2_Q2_USD":-4.18,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-149000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":19196798.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":19200747.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-1103000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":0.0,"CommonStockValue_0_Q2_USD":192000.0,"LongTermNotesPayable_0_Q2_USD":7865000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":75000.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":-4127000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":1627000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-80154000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-36421000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-75921000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":478000.0,"OtherOperatingIncomeExpenseNet_1_Q2_USD":2374000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.01,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":4394000.0,"CommonStockSharesOutstanding_0_Q2_shares":19240295.0,"EarningsPerShareDiluted_1_Q2_USD":-1.9,"EarningsPerShareDiluted_2_Q2_USD":-4.18,"Goodwill_0_Q2_USD":17260000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":4233000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":-2721000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-66185000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":19196798.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":19200747.0,"LiabilitiesCurrent_0_Q2_USD":26993000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":186286000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":8966000.0,"NetIncomeLossAvailableToCommonStockholdersDiluted_2_Q2_USD":-80154000.0,"NetIncomeLossAvailableToCommonStockholdersDiluted_1_Q2_USD":-36421000.0,"AdditionalPaidInCapital_0_Q2_USD":464665000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":186000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":868000.0,"NetIncomeLoss_2_Q2_USD":-80154000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-64986000.0,"CommonStockSharesAuthorized_0_Q2_shares":60000000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-346974000.0,"IncreaseDecreaseInOtherOperatingLiabilities_2_Q2_USD":-4412000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":2428000.0,"OperatingIncomeLoss_2_Q2_USD":-72810000.0,"OperatingIncomeLoss_1_Q2_USD":-33032000.0,"AccountsPayableTradeCurrent_0_Q2_USD":5704000.0,"NotesPayableCurrent_0_Q2_USD":1992000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_Q2_USD":35.07,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":219497000.0,"PreferredStockSharesAuthorized_0_Q2_shares":50000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":6566000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":3504000.0,"OperatingExpenses_2_Q2_USD":77204000.0,"OperatingExpenses_1_Q2_USD":35460000.0,"ProfitLoss_2_Q2_USD":-80154000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":3301000.0,"OtherLiabilitiesCurrent_0_Q2_USD":1250000.0,"StockholdersEquity_0_Q2_USD":113504000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":279000.0,"AccretionExpense_2_Q2_USD":6248000.0,"AmortizationOfFinancingCostsAndDiscounts_2_Q2_USD":235000.0,"OtherOperatingIncomeExpenseNet_2_Q2_USD":-4154000.0,"Ticker":"ALBO","CIK":"1322505","name":"ALBIREO PHARMA, INC.","OfficialName":"Albireo Pharma Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"688702712.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210805"}]